211At-NCS-13R4

211At-NCS-13R4 is a radiolabeled monoclonal antibody used as a non-binding isotype control in preclinical studies of alpha-emitting radioimmunotherapy (RIT). It consists of the 13R4 antibody framework, which does not target any known human antigens in the experimental models, conjugated to the alpha-emitting radioisotope astatine-211 (211At) via an isothiocyanatophenethyl-ureido-closo-decaborate(2-) (B10-NCS) boron cage linker. In research conducted by the Fred Hutchinson Cancer Center and the University of Washington, 211At-NCS-13R4 is utilized in disseminated acute myeloid leukemia (AML) mouse models to establish the baseline for non-specific radiation-induced toxicity and anti-tumor effects. This allows for the accurate assessment of the target-specific efficacy of CD45-directed RIT candidates, such as 211At-NCS-HuBC8.